educational conferences that bring the state-of-the-art science from leading cannabis researchers throughout the world. While the federal placement of cannabis in Schedule I (forbidden category) of the Controlled substances has greatly restricted clinical trials on its potential benefits, the amount of basic research on THC and cannabis for potential harm is quite extensive. Our goal was and is to put these scientists in the spotlight and let healthcare professionals and the public learn about their work. Our primary target for our conferences is the healthcare professional, but all are open to the public as well. We have many patients and/or their family members attend who want to learn more about cannabis because their own healthcare provider either doesn’t support their use of cannabis or has little to no knowledge about cannabis.
The conference faculty is interdisciplinary and we bring the best of the best. We bring leading scientists from outside the U.S. such as Raphael Mechoulam, PhD (Israel), Manuel Guzman, PhD (Spain), Vincenzo Di Marzo, PhD (Italy), Roger Pertwee, PhD (UK), and Mark Ware, MD (Canada).
We bring pioneer researchers and clinicians from the U.S. such as Michael Aldrich, PhD, Ethan Russo, MD, Donald Abrams, MD, Allyn Howlett, PhD, Melanie Dreher, RN, PhD, Donald Tashkin, MD, Andrew Weil, MD, Lester Grinspoon, MD and others. We bring the federal patients as well as other patients to help put a face with the science. We bring policy makers to shed light on the changing laws on the state, federal and international levels.
16 17
The Seventh National Clinical Conference on Cannabis Therapeutics The Endocannabinoid System: Clinical Applications for Health Care in Tucson, Arizona (2012)